2025
Psychometric properties of the Spanish Yale-Brown Obsessive-Compulsive Scale – Second Edition
Storch E, Cheng J, Higham M, Muñoz J, Cruz V, Berrones D, Obando D, Anderberg J, Frederick R, Tapia-Cuevas V, Muñoz M, Villar C, Moya P, Ochoa-Panaifo M, Mallen M, Wiese A, Pinciotti C, Sagarnaga M, McGuire J, Onyeka O, Moyano M, genomics L, Adorno V, Agostini V, Aguilar W, Aguirre C, Alvarado-Quiroz V, Ancalade N, Anderberg J, Aponte D, Espinosa A, Arnold P, Ascencio-Chicana E, Atkinson E, Ayala J, Aziz H, Aguirre T, Barrera C, Contreras J, Barry K, Belanger A, Benitez L, Berrones D, Best J, Bigdeli T, Bommiasamy H, Borda T, Boyajian L, Muñoz D, Browning L, Burton C, Busto C, Buxbaum J, Rivera R, Callahan J, Gomez C, Canchari E, Carrrera M, Chang A, Chazelle E, Cheng J, Chire J, Muñoz M, Cicero D, Cifuentes-Espinoza A, Quiroz P, Colombo G, Comer J, Condori-Apaza L, Cortina J, Crivelari J, Crosbie J, Crowley J, Cruz V, Cruz I, Cunning A, Perez G, Dailey M, Dang B, Dawson A, del Río D, Dev A, Diaz S, Fay L, Fernandez A, Figueroa E, Flecha L, Flores-Garcia Á, Forero D, Franklin M, Frederick R, Furr J, Gamarra O, Garay-Contreras C, García-Bravo N, García-Jaimes C, Garrison S, Giusti-Rodriguez P, Gonzalez A, González R, Gonzalez-Barrios P, Goodman W, Gorosito J, Grice D, Guintivano J, Guttfreund D, Halvorsen M, Miles J, Hettema J, Hovey J, Irreño-Sotomonte J, Janssen-Aguilar R, Jensen M, Reynolds A, Jiwani R, Johnson J, Joutte S, Lujambio J, Kehrer S, Kennedy J, Lack C, Lanzagorta N, Lázaro-Muñoz G, Longhurst M, Martinez D, Luna E, MacLellan A, Quispe D, Marques A, Marquez M, Martinez M, Martínez G, Mallen M, Martinez-Gonzalez K, de Los Angeles Matos M, Mattheisen M, McGuire J, McKay D, McOmber C, Minaya C, Miño T, Mithani S, Morales-Rivero A, Moya P, Moyano M, Muñoz J, Muñoz M, Nicolini H, Bracho A, Bracho B, O'Higgins M, Obando D, Ochoa M, Ochoa-Panaifo M, Castaman L, Balmaceda T, Tobar M, Onyeka O, Ortega I, Paredes-Linares V, Pato M, Paz y Miño M, de Leon E, Orellana J, Pereira S, Duarte T, Phan A, Placencia M, Ponce L, Poovey K, Prieto M, Qiao T, Quiroz-Padilla M, Correa M, Heros A, Ramos R, Ramos I, Ramsey K, Rancourt D, da Silva K, Espinosa R, Richter P, Rodriguez C, Barajas S, Romero M, Ruggero C, Ruiz-Chow A, Sadruddin Z, Sagarnaga M, Salhadar N, Sanchez N, Schachar R, Segovia L, Seligman L, Siegel I, Staples C, Stewart S, Storch E, Tapia-Cuevas V, Timpano K, Tonarelli S, la Garza B, Trujillo A, Villar C, Valdés C, Vallejo-Silva A, Mamani K, Vargas-Medrano J, Vásquez M, Vásquez-Ayala J, Vásquez-Suyo I, Mellstrieng A, Vergara M, Vidal-Martinez G, Vollaro C, Wiese A, Wilkerson S, Zai G, Zappa L, Cruz V, Zepeda-Burgos R, Zoghbi A, Group B, Alves G, Alves G, Barbosa I, Cappi C, Carneiro M, Costa D, Delage F, Dreher C, Ferrão Y, Ferreira G, Fontenelle L, Fragoso D, Lima M, Menezes G, Miguel E, Moreira-de-Oliveira M, Stumpf B, Quarantini L, Quarantini-Alvim Y, Ramos V, Rosario M, Sampaio A, Saraiva L, Shavitt R, Goodman W, Crowley J. Psychometric properties of the Spanish Yale-Brown Obsessive-Compulsive Scale – Second Edition. Psychiatry Research 2025, 348: 116456. PMID: 40188616, PMCID: PMC12082261, DOI: 10.1016/j.psychres.2025.116456.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderY-BOCS-IIAnxiety symptomsYale-Brown Obsessive-Compulsive Scale-Second EditionSeverity of obsessive-compulsive symptomsPsychometric propertiesYale-Brown Obsessive-Compulsive ScaleObsessive-compulsive symptom severityClinician-rated measuresObsessive-Compulsive ScaleObsessive-compulsive symptomsFactor analysisMeasures of depressionSecond editionBattery of measuresOne-factor solutionConfirmatory factor analysisSatisfactory construct validityExploratory factor analysisObsession severityCompulsion severitySymptom severityTotal severitySymptom ChecklistTotal scoreEffect of Esketamine on Depressive Symptoms in Adolescents with Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled Study
Kosik-Gonzalez C, Fu D, Chen L, Lane R, Bloch M, DelBello M, Moreno C, Drevets W, Canuso C. Effect of Esketamine on Depressive Symptoms in Adolescents with Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled Study. Journal Of The American Academy Of Child & Adolescent Psychiatry 2025 PMID: 40058488, DOI: 10.1016/j.jaac.2025.02.015.Peer-Reviewed Original ResearchChildren's Depression Rating Scale-RevisedMajor depressive disorderDepressive disorderDepressive symptomsEsketamine dosesSymptoms of major depressive disorderCDRS-R total scoreEsketamine nasal sprayEvidenced-based psychotherapySeverity of suicidalityImprove depressive symptomsReducing depressive symptomsEffects of esketamineIntentional self-injuryImminent riskIntranasal esketamineOral antidepressantSelf-injurySuicidal ideationEnd-point changesAnalysis of covarianceScale-RevisedBetween-group differencesEsketamineTotal scoreEmbodied Cognition and Alcohol Use Disorder: Frequency of Impairments and Relationship to Neurocognitive Assessments
Bell M, Weinstein A, Ciosek D, Reilly S, Wang Y, Yoon G. Embodied Cognition and Alcohol Use Disorder: Frequency of Impairments and Relationship to Neurocognitive Assessments. Brain Sciences 2025, 15: 228. PMID: 40149750, PMCID: PMC11940586, DOI: 10.3390/brainsci15030228.Peer-Reviewed Original ResearchAlcohol use disorderEmbodied cognitionTotal scoreExecutive functionUse disorderNeurocognitive assessmentCognitive declineMeasure executive functionFrequency of impairmentPotential protective factorsPremorbid IQEF impairmentsMemory domainDelayed RecallOverall impairmentEF domainsCognitive processesNeurocognitive testsConcurrent validityFrequent impairmentCognitionSelf-RegulationCognitive scienceImpairmentProtective factorsLUMATEPERONE IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER AND BIPOLAR DISORDER WITH ANXIOUS DISTRESS AND MIXED FEATURES
Bhagwagar *, Kozauer S, Earley W, Huo J, Sachs G, Durgam S. LUMATEPERONE IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER AND BIPOLAR DISORDER WITH ANXIOUS DISTRESS AND MIXED FEATURES. The International Journal Of Neuropsychopharmacology 2025, 28: i316-i316. PMCID: PMC11814723, DOI: 10.1093/ijnp/pyae059.563.Peer-Reviewed Original ResearchClinical Global Impression Scale-SeverityMajor depressive disorderMADRS total scoreClinical Global Impression Scale-Severity scoresAnxious distressBipolar depressionBipolar II disorderDSM-5Bipolar disorderTotal scoreII disorderBipolar IDepressive disorderDepressive episodeAssociated with major depressive disorderDepression Rating ScaleDSM-5 criteriaBipolar disorder diagnosisPost-hoc analysis of studyIncreased suicide riskPoor treatment responseSingle-item scoresEpisode specifierTreat schizophreniaDisorder diagnosisCELECOXIB ADDED TO RISPERIDONE FOR DEPRESSIVE SYMPTOMS IN FIRST-EPISODE AND DRUG NAÏ VE SCHIZOPHRENIA: PHARMACOGENETIC IMPACT OF BDNF GENE POLYMORPHISMS
Wang *, Chen X, Tian Y, Yu Z, Chen D, Xiu M, Kosten T, Zhang X. CELECOXIB ADDED TO RISPERIDONE FOR DEPRESSIVE SYMPTOMS IN FIRST-EPISODE AND DRUG NAÏ VE SCHIZOPHRENIA: PHARMACOGENETIC IMPACT OF BDNF GENE POLYMORPHISMS. The International Journal Of Neuropsychopharmacology 2025, 28: i158-i159. PMCID: PMC11815116, DOI: 10.1093/ijnp/pyae059.274.Peer-Reviewed Original ResearchHamilton Depression Rating ScaleBrain-derived neurotrophic factorPositive and Negative Syndrome ScaleBrain-derived neurotrophic factor serum levelsBrain-derived neurotrophic factor levelsSchizophrenia patientsTreatment of depressionDepressive symptomsPositive symptomsFirst-episodeSCZ patientsHamilton Depression Rating Scale total scoreBrain-derived neurotrophic factor systemComorbid major depressive disorderTreatment response to antidepressantsTotal scoreEarly stages of schizophreniaBrain-derived neurotrophic factor polymorphismsBrain-derived neurotrophic factor genotypePathogenesis of depressive symptomsBrain-derived neurotrophic factor gene polymorphismImprove treatment of depressionBrain-derived neurotrophic factor signalingHealthy controlsAmerican Journal of PsychiatryHealth Status Improvement After Peripheral Vascular Intervention: Insights From the LIBERTY 360 Study
Mosarla R, Chowdhury M, Smolderen K, Mena-Hurtado C, Spertus J, Yeh R, Secemsky E. Health Status Improvement After Peripheral Vascular Intervention: Insights From the LIBERTY 360 Study. The American Journal Of Cardiology 2025, 243: 22-31. PMID: 39894333, DOI: 10.1016/j.amjcard.2025.01.017.Peer-Reviewed Original ResearchPredictor of health statusHealth statusEQ-VASAssociated with health statusHealth status measuresTarget vessel/lesion revascularizationTotal scoreBaseline health statusAll-cause deathImprove health statusPeripheral endovascular interventionsHealth status improvementChronic limb-threatening ischemiaRepeated measures modelPeripheral arterial disease severitySymptomatic peripheral arterial diseaseStatus measuresPeripheral arterial diseaseLimb-threatening ischemiaLong-term improvementPeripheral vascular interventionsStatus improvementHealthMultivariate regressionClaudication
2024
A Psychometric Evaluation of the Parenting Anxious Kids Rating Scale (PAKRS-PR) in a Sample of Families with Clinically Anxious Children
DiFonte M, Sain K, Tolin D. A Psychometric Evaluation of the Parenting Anxious Kids Rating Scale (PAKRS-PR) in a Sample of Families with Clinically Anxious Children. Child Psychiatry & Human Development 2024, 1-10. PMID: 39589720, DOI: 10.1007/s10578-024-01793-0.Peer-Reviewed Original ResearchSessions of cognitive behavioral therapyPsychometric evaluationTreatment-seeking sampleCognitive behavioral therapyAssociated with treatment responseTreatment outcome measuresParent-child dyadsSpecialty outpatient clinicAnxiogenic parentingSample of familiesAnxiety severityBehavioral therapyConvergent validityTotal scalePsychometric propertiesRating ScaleItem levelTotal scoreSubscalesWarmth/supportTreatment responseCronbach's aOutcome measuresParentsAnxietySpesolimab increases the percentage of generalized pustular psoriasis (GPP) patients with clear skin over time as measured by the Physician’s Global Assessment for GPP (GPPGA): Results from the EFFISAYIL® 2 trial
Gottlieb A, Strober B, Merola J, Mostaghimi A, Farberg A, Guercio J, Tang M, Thoma C, Lebwohl M. Spesolimab increases the percentage of generalized pustular psoriasis (GPP) patients with clear skin over time as measured by the Physician’s Global Assessment for GPP (GPPGA): Results from the EFFISAYIL® 2 trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s490. DOI: 10.25251/skin.8.supp.490.Peer-Reviewed Original ResearchGeneralized pustular psoriasisPhysician global assessmentSkin symptomsPustular psoriasisGlobal assessmentProportion of patientsPercentage of patientsTreating generalized pustular psoriasisLife-threatening skin diseaseSignificant patient burdenYears of ageDosing regimenPediatric patientsClear skinSpesolimabPatientsContinuous treatmentMonoclonal antibodiesSkin diseasesPatient burdenSymptomsPsoriasisTotal scoreSkinTreatmentTranscranial Direct Current Stimulation Combined With Repetitive Transcranial Magnetic Stimulation for Depression
Zhou D, Li X, Wei S, Yu C, Wang D, Li Y, Li J, Liu J, Li S, Zhuang W, Li Y, Luo R, Liu Z, Liu J, Xu Y, Fan J, Zhu G, Xu W, Tang Y, Cho R, Kosten T, Zhang X. Transcranial Direct Current Stimulation Combined With Repetitive Transcranial Magnetic Stimulation for Depression. JAMA Network Open 2024, 7: e2444306. PMID: 39535797, PMCID: PMC11561687, DOI: 10.1001/jamanetworkopen.2024.44306.Peer-Reviewed Original ResearchConceptsSham repetitive transcranial magnetic stimulationActive repetitive transcranial magnetic stimulationSham transcranial direct current stimulationRepetitive transcranial magnetic stimulationActive transcranial direct current stimulationTranscranial direct current stimulationTranscranial magnetic stimulationPrimary outcomeIntention-to-treat approachRTMS interventionSham-controlled randomized clinical trialRepetitive transcranial magnetic stimulation sessionsDirect current stimulationMagnetic stimulationSafety of repetitive transcranial magnetic stimulationDepressive disorderMain OutcomesRandomized clinical trialsTotal scoreCurrent stimulationTranscranial direct current stimulation sessionsDorsolateral prefrontal cortexBaseline to week 2Hamilton Depression Rating ScaleRating ScaleSex-specific associations between 10-year cardiovascular risk, clinical symptoms and cognitive impairments in schizophrenia
Jin X, Lu C, Liu N, Li Y, Dong Y, Wang X, Li S, Li J. Sex-specific associations between 10-year cardiovascular risk, clinical symptoms and cognitive impairments in schizophrenia. Journal Of Neural Transmission 2024, 132: 313-322. PMID: 39387913, DOI: 10.1007/s00702-024-02842-7.Peer-Reviewed Original ResearchPositive and Negative Syndrome ScaleRepeatable Battery for the Assessment of Neuropsychological StatusPsychiatric symptomsNegative symptomsCognitive functionSex differencesAssessment of Neuropsychological StatusPANSS total scoreNegative Syndrome ScaleFramingham risk scoreSignificant sex differencesSyndrome ScalePsychopathology scoresImmediate memoryNeuropsychological StatusCardiovascular riskSCZTotal scoreCognitive impairmentCardiovascular diseaseSex-specific associationsFasting venous blood samplesHigher Framingham risk scoreGlycolipid metabolism indexesSymptomsTargeting Chronic Pain Care to Rural Women Veterans: A Feasibility Pilot
Garvin L, Driscoll M, Steffensmeier K, Johnson N, Adamowicz J, Obrecht A, Hart K, Rothmiller S, Sibenaller Z, Stout L, Richards C, Vander Weg M, Lund B, Hadlandsmyth K. Targeting Chronic Pain Care to Rural Women Veterans: A Feasibility Pilot. Psychological Services 2024 PMID: 39374152, PMCID: PMC12108542, DOI: 10.1037/ser0000909.Peer-Reviewed Original ResearchPain self-management interventionSelf-management interventionsWomen veteransChronic painRural women veteransChronic pain careEnjoyment of lifePreliminary data supportPain careFeasibility pilotGlobal Impression of Change scaleThree-item scaleNon-HispanicTelehealth platformQualitative interviewsThemes of connectionBaseline scoresChange ScaleSignificant barriersVeteransTotal scoreQualitative dataInterventionRural dwellingsStudy completionPsychosocial outcomes with the Omnipod® 5 Automated Insulin Delivery System in caregivers of very young children with type 1 diabetes
MacLeish S, Hood K, Polonsky W, Wood J, Bode B, Forlenza G, Laffel L, Buckingham B, Criego A, Schoelwer M, DeSalvo D, Sherr J, Hansen D, Conroy L, Huyett L, Vienneau T, Ly T, Group F. Psychosocial outcomes with the Omnipod® 5 Automated Insulin Delivery System in caregivers of very young children with type 1 diabetes. Diabetes Obesity And Metabolism 2024, 26: 5569-5579. PMID: 39300963, PMCID: PMC11949198, DOI: 10.1111/dom.15906.Peer-Reviewed Original ResearchPsychosocial outcomesSleep qualityEvaluate psychosocial outcomesPittsburgh Sleep Quality Index total scoreWell-beingType 1 diabetesSatisfaction survey scoresYoung childrenBurden caregiversAid useOverall sleep qualityAutomated Insulin DeliverySystem usabilityCaregiversSurvey scoresDiabetes managementPerceived system usabilityGlycaemic outcomesTotal scoreSleep durationDelivery satisfactionGlycaemic metricsSubscalesOutcomesUnique challengesTreating new-onset cognitive complaints after risk-reducing salpingo-oophorectomy: A randomized controlled crossover trial of lisdexamfetamine
Metcalf C, Page C, Stocker B, Johnson R, Duffy K, Sammel M, Loughead J, Epperson C. Treating new-onset cognitive complaints after risk-reducing salpingo-oophorectomy: A randomized controlled crossover trial of lisdexamfetamine. Gynecologic Oncology 2024, 190: 62-69. PMID: 39146756, PMCID: PMC11702344, DOI: 10.1016/j.ygyno.2024.07.689.Peer-Reviewed Original ResearchRisk-Reducing Salpingo-OophorectomySelf-report measures of executive functionBrown Attention Deficit Disorder ScaleMeasures of executive functionMeasures of cognitive functionWorking memory performanceExecutive function difficultiesMeasures of attentionSelf-report measuresTrial completion ratesGenetically at-riskRandomized controlled crossover trialAttention/working memoryExecutive functionWorking memoryDisorder ScaleMemory performanceSustained attentionCognitive complaintsCognitive tasksLisdexamfetamineCognitive functionActive medicationTotal scoreFunctional difficultiesEfficacy and tolerability of antipsychotic polypharmacy for schizophrenia spectrum disorders. A systematic review and meta-analysis of individual patient data
Lochmann van Bennekom M, IntHout J, Gijsman H, Akdede B, Yağcıoğlu A, Barnes T, Galling B, Gueorguieva R, Kasper S, Kreinin A, Nielsen J, Nielsen R, Remington G, Repo-Tiihonen E, Schmidt-Kraepelin C, Shafti S, Xiao L, Correll C, Verkes R. Efficacy and tolerability of antipsychotic polypharmacy for schizophrenia spectrum disorders. A systematic review and meta-analysis of individual patient data. Schizophrenia Research 2024, 272: 1-11. PMID: 39142215, DOI: 10.1016/j.schres.2024.07.035.Peer-Reviewed Original ResearchClinical Global Impression ScaleSchizophrenia spectrum disordersPositive and Negative Syndrome ScaleBaseline PANSS total scoreAntipsychotic polypharmacyPANSS total scoreTotal scorePositive symptomsPsychotic patientsPositive and Negative Syndrome Scale positive symptom subscaleNegative symptom subscale scoreSubgroup of psychotic patientsBaseline positive symptomsExtrapyramidal side effectsNegative Syndrome ScalePositive symptom subscaleSecond-generation antipsychoticsGlobal Impression ScaleModerators of efficacySeverely psychotic patientsStudy-level moderatorsStudy discontinuationSymptom subscale scoresAntipsychotic monotherapySyndrome ScaleThe Imperfect Yet Valuable Difficulties in Emotion Regulation Scale: Factor Structure, Dimensionality, and Possible Cutoff Score
Erez C, Gordon I. The Imperfect Yet Valuable Difficulties in Emotion Regulation Scale: Factor Structure, Dimensionality, and Possible Cutoff Score. Assessment 2024, 32: 778-795. PMID: 39054870, DOI: 10.1177/10731911241261168.Peer-Reviewed Original ResearchEmotion Regulation ScaleEmotion regulationRegulation ScaleCutoff scoreDERS total scoreAssess emotion regulationER difficultiesSelf-reported dataBifactor modelUnidimensional solutionFactor structureTotal scoreSelf-ReportLife satisfactionPsychopathologyClinical samplesEmotionsGroup interactionMultidimensional scalingScoresBifactorScaleDifficultiesSubfactorsPersonsUnited States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use
Habib A, Klink A, Muppidi S, Parthan A, Sader S, Balanean A, Gajra A, Nowak R, Howard J. United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use. Journal Of Neurology 2024, 271: 6114-6126. PMID: 39052039, PMCID: PMC11377470, DOI: 10.1007/s00415-024-12569-w.Peer-Reviewed Original ResearchMinimal symptom expression’Minimal manifestation statusGeneralized myasthenia gravisEculizumab initiationEculizumab treatmentTotal scoreMG-ADLPrednisone dosageMyasthenia gravisMethodsA retrospective chart reviewComplement C5 inhibitor eculizumabSteroid-sparing effectAssociated with sustained improvementOpen-label extensionEffectiveness of eculizumabImmunosuppressive therapy useConcomitant medication useRetrospective chart reviewNonsteroidal immunosuppressive therapyMyasthenia Gravis-ActivitiesTreatment-refractoryC5 inhibitor eculizumabDiscontinue prednisoneImmunosuppressive therapySymptom expressionRelationship between plasma TNF-α levels and agitation symptoms in first episode patients with schizophrenia
Wang X, Chen W, Gou M, Li W, Li N, Tong J, Zhou Y, Xie T, Yu T, Feng W, Li Y, Chen S, Tian B, Tan S, Wang Z, Pan S, Luo X, Zhang P, Huang J, Tian L, Li C, Tan Y. Relationship between plasma TNF-α levels and agitation symptoms in first episode patients with schizophrenia. BMC Psychiatry 2024, 24: 480. PMID: 38956509, PMCID: PMC11218378, DOI: 10.1186/s12888-024-05796-y.Peer-Reviewed Original ResearchConceptsPositive and Negative Syndrome ScalePlasma TNF-a levelsAgitation symptomsPANSS-ECEpisode patientsTNF-a levelsPositive and Negative Syndrome Scale total scorePANSS-EC scoreNegative Syndrome ScaleSymptoms of schizophreniaPathophysiology of schizophreniaEnzyme-linked immunosorbent assayTNF-aR1 levelSyndrome ScalePlasma levels of tumor necrosis factor-alphaLevels of tumor necrosis factor-alphaSchizophreniaTotal scoreTumor necrosis factor-alphaNecrosis factor-alphaPlasma TNF-aHealthy controlsFEPImmune abnormalitiesCognitive enhancing effect of rTMS combined with tDCS in patients with major depressive disorder: a double-blind, randomized, sham-controlled study
Li X, Liu J, Wei S, Yu C, Wang D, Li Y, Li J, Zhuang W, Luo R, Li Y, Liu Z, Su Y, Liu J, Xu Y, Fan J, Zhu G, Xu W, Tang Y, Yan H, Cho R, Kosten T, Zhou D, Zhang X. Cognitive enhancing effect of rTMS combined with tDCS in patients with major depressive disorder: a double-blind, randomized, sham-controlled study. BMC Medicine 2024, 22: 253. PMID: 38902735, PMCID: PMC11188255, DOI: 10.1186/s12916-024-03443-7.Peer-Reviewed Original ResearchConceptsRBANS total scoreRepetitive transcranial magnetic stimulationTranscranial direct current stimulationMDD patientsTotal scoreHDRS-24Transcranial direct current stimulation groupDepressive disorderImmediate memoryDepressive symptomsCognitive dysfunctionHamilton Depression Rating ScaleTreatment of cognitive dysfunctionDepressed response ratesDepression Rating ScaleCognitive enhancing effectsTreating cognitive dysfunctionImprove neurocognitive impairmentsActive rTMS groupDouble-blindSafety of repetitive transcranial magnetic stimulationTranscranial direct current stimulation treatmentMDD inpatientsRepeatable BatterySessions of treatmentSpectral Brain Graph Neural Network for Prediction of Anxiety in Children with Autism Spectrum Disorder
Duan P, Dvornek N, Wang J, Eilbott J, Du Y, Sukhodolsky D, Duncan J. Spectral Brain Graph Neural Network for Prediction of Anxiety in Children with Autism Spectrum Disorder. 2011 IEEE International Symposium On Biomedical Imaging: From Nano To Macro 2024, 00: 1-5. PMID: 39697611, PMCID: PMC11655121, DOI: 10.1109/isbi56570.2024.10635753.Peer-Reviewed Original ResearchGraph neural networksFunctional magnetic resonance imagingAutism spectrum disorderNeural networkCurrent graph neural networksSpectrum disorderMASC-2Spectral analysis algorithmAnalysis algorithmGraph-based networkMultidimensional Anxiety ScaleFast Fourier transformPredictive of anxietyDaily anxiety levelsExtract hidden informationBrain functional networksPower spectrum densityNode featuresNetwork performanceComorbid anxietyBrain mechanismsHidden informationCorrelated featuresAnxiety ScaleTotal score0920 Sleep Health and Cognitive Symptoms in Adults with Inflammatory Bowel Disease
Al-Saleh S, Kamp K, Kane S, Redeker N, Conley S. 0920 Sleep Health and Cognitive Symptoms in Adults with Inflammatory Bowel Disease. Sleep 2024, 47: a395-a395. DOI: 10.1093/sleep/zsae067.0920.Peer-Reviewed Original ResearchPittsburgh Sleep Quality IndexPittsburgh Sleep Quality Index total scorePoor sleep healthSleep healthFACT-CogIBD disease activityManitoba IBD IndexTotal scoreCognitive symptomsCognitive Impairment QuestionnairePerceived cognitive impairmentInflammatory bowel diseaseMeasures of sleep healthSleep Quality IndexStudy of adultsSelf-reported dataClinically active inflammatory bowel diseaseActive inflammatory bowel diseaseAssociated with 4Associated with troubleImpairment QuestionnaireAssociated with 2Descriptive statisticsPoint-biserial correlationAssociated with higher frequency
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply